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Abstract  
Mutations in SCN2A cause epilepsy syndromes of variable severity including neonatal-infantile seizures. In one case, we 
previously described additional childhood-onset episodic ataxia. Here, we corroborate and detail the latter phenotype in 
three further cases. We describe the clinical characteristics, identify the causative SCN2A mutations and determine their 
functional consequences using whole-cell patch-clamping in mammalian cells. In total, four probands presented with 
neonatal-onset seizures remitting after five to 13 months. In early childhood, they started to experience repeated episodes 
of ataxia, accompanied in part by headache or backpain lasting minutes to several hours. In two of the new cases, we 
detected the novel mutation p.Arg1882Gly. While this mutation occurred de novo in both patients, one of them carries an 
additional known variant on the same SCN2A allele, inherited from the unaffected father (p.Gly1522Ala). Whereas 
p.Arg1882Gly alone shifted the activation curve by -4 mV, the combination of both variants did not affect activation, but 
caused a depolarizing shift of voltage-dependent inactivation, and a significant increase in Na+ current density and 
protein production. p.Gly1522Ala alone did not change channel gating. The third new proband carries the same de novo 
SCN2A gain-of-function mutation as our first published case (p.Ala263Val). Our findings broaden the clinical spectrum 
observed with SCN2A gain-of-function mutations, showing that fairly different biophysical mechanisms can cause a 
convergent clinical phenotype of neonatal seizures and later onset episodic ataxia. 
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Introduction  
Gene discovery in epilepsy and related neurological syndromes, such as migraine, paroxysmal dyskinesia and episodic 
ataxia, has revealed that mutations in ion channels, transporters, or synaptic proteins play a crucial role in their 
pathophysiology [1-3]. These mutations affect the excitability of different neuronal subtypes and compartments. The 
altered excitability, sometimes provoked by typical decompensating triggers, episodically induces a dysfunction of 
neuronal networks in distinct brain regions thereby causing well-defined paroxysmal clinical symptoms. Beside ‘pure’ 
syndromes with only one characteristic clinical feature, several overlap syndromes with epilepsy as a core phenotype 
have been described [4,5]. 
The neuronal voltage-gated Na+ channel NaV1.2, encoded by the SCN2A gene, is mutated in benign familial neonatal-
infantile seizures (BFNIS), an autosomal dominant epilepsy syndrome characterized by transient seizures in the first 
weeks or months of life [6,7]. These mutations mainly lead to gain-of-function defects causing neuronal 
hyperexcitability [8,7]. More severe, non-familial phenotypes with neonatal onset seizures caused by de novo SCN2A 
mutations are increasingly described [9-14]. One loss-of-function mutation causes epileptic encephalopathy with later 
onset [15]. 
We previously described a single patient with neonatal-onset, relatively severe epilepsy resolving at 13 months of age, 
with episodes of ataxia, myoclonus and pain starting at 18 months of age. We identified a de novo missense mutation in 
SCN2A showing a gain-of-function defect [3]. Here, we describe three further independent cases with neonatal-onset 
seizures and episodic ataxia starting in early childhood. We reveal the common clinical features, the underlying SCN2A 
mutations and their pathophysiological mechanisms. 
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Materials and methods 
Patients 
Clinical evaluation of the first new case (patient #1) and follow-up of the previously described one (#4) were performed 
in Helsinki. The other two new patients were examined at the University Clinic Giessen (patient #2) or at the Epilepsy 
Center Kork (patient #3). All patients were selected from routine clinical presentations in the respective centers and 
underwent subsequent genetic testing due to clinical suspicion of an SCN2A defect, since they presented highly similarly 
as case #4. 
Molecular Genetics 
Patient #1 underwent direct (Sanger) sequencing of SCN2A. For patients #2 and #3 an epilepsy gene panel screening was 
performed as reported previously [16]. Confirmation of the mutations and segregation was performed by Sanger 
sequencing. Long range PCR was used to determine if the two variants detected in patient #2 were on the same allele. 
For SCN2A sequencing genomic DNA was isolated from EDTA-blood. The coding exons and exon-intron boundaries of 
SCN2A in patients #2 and #3, and mutation-carrying exons in their parents, were amplified (primers available upon 
request). SCN2A in patient #4 and her parents was amplified (primers available upon request) by the Qiagen Multiplex 
PCR kit, and by the Expand Long Range PCR kit (Cat. No. 04829034001 Roche, Mannheim, Germany) on a Biometra 
T3 thermocycler (Biometra, Göttingen, Germany). Long range PCR products were cloned (TOPO® XL PCR Cloning 
Kit, Cat. No. K4700-10) and finally sequenced. For long range PCR, covering both detected variants chromosomal 
position 166242926-66246608 (forward: ATCGTGCCACTGCACTCCAACC, reverse: 
CTATCGTCTGAGTAGCCATTACGCC) was amplified resulting in a 3682 bp fragment. Sequencing reactions were 
performed using ABI PRISM® BigDye® Terminator v3.1Cycle Sequencing Kit (Applied Biosystems, Weiterstadt, 
Germany). Capillary electrophoresis was conducted on an ABI PRISM® 3100 Genetic Analyzer (Applied Biosystems, 
Weiterstadt, Germany) or an ABI 3730 DNA Analyzer (Perkin Elmer, Foster City, CA, U.S.A.). 
Mutagenesis  
To engineer the mutations into the adult splice variant of the human NaV1.2 channel, site-directed mutagenesis was 
performed using Quickchange® II XL (Agilent Technologies, Santa Clara, CA, USA; primers are available upon 
request) for the R1882G mutation and GoTaq® Long PCR Master Mix (Promega Corporation, Madison, WI, USA; 
primers are available upon request) for the G1522A and G1522A + R1882G mutations. Before used in experiments, the 
mutant cDNA was fully resequenced to verify the introduced mutations and exclude any additional sequence alterations. 
GlaxoSmithKline (Brentford, UK) kindly provided the human Na+ channel subunits hβ1 and hβ2 in the pCLH vector. The 
hygromycin coding region in the vector was exchanged with the sequence coding for either enhanced green fluorescent 
protein (EGFP) or CD8 marker genes to obtain pCLH-hβ1-EGFP and pCLH-hβ2-CD8 [3,17]. 
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Transfection and expression in tsA201 cells  
Human tsA201 cells were cultured at 37°C, with 5% CO2 humidified atmosphere and grown in 89% Dulbecco’s 
modified Eagle medium (Invitrogen, Carlsbad, CA,USA) + 10% (v/v) foetal bovine serum (PAN-Biotech GmbH, 
Aidenbach, Germany) + 1% L-Glutamin 200 mM (Biochrom GmbH, Berlin, Deutschland). Transfections using Mirus 
TransIT®-LT1 reagent (Madison, WI 53711 USA) were performed for transient expression of wild-type or mutant Na+ 
channel α-subunits together with β1- and β2-subunits in tsA-201 cells. For co-expression of α- and both β-subunits 2.4 µg 
of total DNA (2.0 µg α-subunit, 0.2 µg β1-subunit and 0.2 µg β2-subunit) was transfected in a molar ratio of 1:1:1. Anti-
CD8 antibody-coated microbeads (Dynabeads M450, Dynal, Norway) were suspended in phosphate buffered saline and 
added to the cells. Cells positive for both CD8 antigen and EGFP fluorescence were used for electrophysiological 
recordings.  
Western Blot 
For protein identification we applied 35 µg per line of total cell lysate on a 6% SDS gel. After separation and blotting, 
the Protran® Nitrocellulose Membranes was blocked with 5% skim milk powder/PBS/0,1% Tween 20 and incubated 
with mouse monoclonal anti-SCN2A antibody 1:500 (overnight, 4 °C) in 1% skim milk powder/PBS/0,1% Tween 20. As 
secondary antibody HRP conjugated goat anti-mouse serum 1:10.000 (1 h, RT) was used. Western Blots were developed 
using the Mini-PROTEAN® Tetra Cell according to the manufactures procedures. Quantification of signals was 
performed using ImageJ software (NIH, Bethesda, MD). Expression of NaV1.2 proteins were normalized to 
corresponding Vinculin signals in total lysates and pooled from different experiments.  
Electrophysiology 
Standard whole-cell patch clamp recordings were performed using an Axopatch 200B amplifier, a Digidata 1320A 
digitizer and pCLAMP 8 data acquisition software (Axon Instruments, Union City, CA, USA), as has been described 
before [7]. Leakage and capacitive currents were automatically subtracted using a pre-pulse protocol (-P/4). Currents 
were filtered at 5 kHz and digitized at 20 kHz. Cells were visualized using an inverted microscope (Axio-Vert.A1; 
Zeiss). All recordings were performed at room temperature of 21–23°C. Na+ currents of 1-12 nA were recorded from 
transfected tsA201 cells 10 min after establishing the whole cell configuration. Borosilicate glass pipettes had a final tip 
resistance of 1-2 MΩ when filled with internal recording solution (see below). We carefully checked that the maximal 
voltage error due to residual series resistance after up to 95% compensation was always <5 mV. The pipette solution 
contained (in mM): 5 NaCl, 2 MgCl2, 5 EGTA, 10 (4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid (HEPES), 130 
CsF (pH 7.4, 290 mOsm). The bath solution contained (in mM) 140 NaCl, 4 KCl, 1 MgCl2, 2 CaCl2, 5 HEPES, 4 
Dextrose (pH 7.4, 300 mOsm). 
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Voltage clamp protocols and data analysis: The activation curve (conductance–voltage relationship) was derived from 
the current–voltage relationship obtained by plotting the peak current over various step depolarizations (7.5 mV steps 
from a holding potential of -140 mV) according to  
)(
)(
revVV
I
Vg
-
=  
with g being the conductance, I the recorded peak current at test potential V, and Vrev the apparent observed Na+ reversal 
potential. 
The voltage-dependence of activation was fit with the following Boltzmann function:  
]}/)exp[(1{
)(
2/1
max
VkVV
g
Vg
-+
=  
with g being the conductance, I the recorded current amplitude at test potential V, Vrev the Na+ reversal potential, gmax the 
maximal conductance, V1/2 the voltage of half-maximal activation and kV a slope factor. Steady-state inactivation was 
determined using 300 ms conditioning pulses to various potentials followed by the test pulse to -20 mV at which the 
peak current reflected the percentage of non-inactivated channels. A standard Boltzmann function was fit to the 
inactivation curves:  
]}/)exp[(1{
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V2/1
max
kVV
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=  
with I being the recorded current amplitude at the conditioning potential V, Imax being the maximal current amplitude, 
V1/2 the voltage of half-maximal inactivation and kV a slope factor. For analysis of the time constants of fast inactivation, 
the cell membrane was depolarized to various test potentials from a holding potential of -140 mV to record Na+ currents.  
A second-order exponential function was best fit to the time course of fast inactivation during the first 70 ms after onset 
of the depolarization, yielding two time constants. The weight of the second slower time constant was relatively small. 
Only the fast time constant, named τh, was therefore used for data presentation in the ‘Results’ section. Persistent Na+ 
currents (ISS, for the ‘steady-state’ current) were determined at the end of depolarizing pulses, lasting 95 ms, to different 
test potentials and are given relative to the initial peak current (IPEAK). Recovery from fast inactivation was recorded from 
holding potentials of -140 mV. Cells were depolarized to -20 mV for 100 ms to inactivate all Na+ channels and then 
repolarized to various recovery potentials (-80, -100 or -120 mV) for increasing duration. A second-order exponential 
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function with an initial delay was best fit to the time course of recovery from inactivation. The faster time constant with 
the much larger relative amplitude, τrec, is shown for data evaluation.  
Data and statistical analysis 
Traces were displayed off-line with Clampfit software of pClamp 10.0 (Axon Instruments). Graphics were generated 
using a combination of Microsoft Excel (Microsoft Corporation, Redmond, WA, USA), and Origin (version 6.1; 
OriginLab Inc., Northampton, MA, USA) software, statistics were performed using SigmaStat 3.1 (Statcon). All data 
were tested for normal distribution. For statistical evaluation t-test was used for comparing two groups. For comparing 
more than two groups, ANOVA on ranks (Kruskal-Wallis-Test) with Dunn’s posthoc test for not normally distributed 
data or one-way ANOVA (Bonferroni posthoc test) was used when data sets were normally distributed. All data are 
shown as means ± SEM, “n” gives the number of cells. For all statistical tests, significance with respect to control is 
indicated on the figures using the following symbols: *p<0.05, **p<0.01, ***p<0.001. 
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Results 
Clinical characterization.  
All four identified patients showed very similar phenotypes with neonatal-onset focal or generalized seizures remitting 
almost completely at 5-13 months old, followed by episodes of ataxia at least once a month starting in early childhood. 
All clinical data are summarized in Table 1 and more detailed case descriptions are given in Online Resource 1.  
Epileptic seizures in patient #1 (Fig. 1a), carrying only the novel de novo missense mutation p.Arg1882Gly (R1882G) 
started at two days old with bilateral tonic-clonic seizures with reduced oxygen saturation and unresponsiveness. The 
seizures were initially pharmacoresistant to phenobarbitone (PB) and valproate (VPA) but stopped by five months of age 
with no recurrences. Since the age of 3.7 years, episodes with slurred speech, ataxia, nausea and headache occur 1-2 
times per month lasting minutes to hours. In patient #2, who carries both R1882G and also the inherited variant 
p.Gly1522Ala (G1522A), multifocal clonic and tonic-clonic seizures lasting 10-120 seconds occurred in the fourth week 
of life, and were well controlled by PB. The girl’s further course was uncomplicated until a series of generalized tonic-
clonic seizures during a febrile infection at five months old. PB was changed to VPA and no further seizures occurred 
after the age of 5 months, also after VPA was finally discontinued at 7 years old. From 20 months of age on, episodes 
characterized by headache, slurred speech, impaired balance and ataxic gait occurred 1-10 times per week lasting 1-5 
minutes. 
Patient #3 (Fig. 1c), carrying the same de novo missense SCN2A mutation as the previously described patient #4 [3] 
(p.Ala263Val, A263V), presented immediately after birth with a marked muscular hypotonia and sleepiness. His 
development was slightly retarded. A first cluster of bilateral tonic seizures occurred at 7 days of life which was resistant 
to different medications (see Table 1). Oxcarbazepine (OXC) and levetiracetam (LEV) were started at 4 months of age, 
and the patient remained seizure-free so far from 7 months on. At 22 months, the parents reported an episode of ataxia 
with mild symptoms starting in the morning and inability to walk or stand in the afternoon. Further similar attacks with 
ataxic gait occurred since then every 10 to 14 days, lasting hours to one day. Formerly described patient #4 presented 
with neonatal-onset seizures with hypomotor semiology followed by tonic-clonic seizures as described previously [3]. 
During treatment with phenytoin (PHT), seizures became much less frequent at the age of 13 months. Since then, he has 
only suffered from three isolated generalized tonic-clonic seizures at the age of 3.5, 6.5 and 14.5 years. The habitual 
headache-ataxia episodes started at 18 months old and were pharmacoresistant [3] until now.  
Episodic ataxia in all four patients responded poorly to any of the medications tried so far (see Table 1, Online Resource 
1 and discussion). 
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Genetics. In both patients #1 and #2 we identified the novel missense mutation c.5644C>G, p.Arg1882Gly (R1882G; 
GeneBank NM_021007.2, NC_000002.11). Sequencing of the parents revealed that the mutation occurred de novo in 
both patients. In addition, the missense variant c.4565G>C, p.Gly1522Ala (G1522A; rs147522594) was identified in 
patient #2. Rs147522594 was also detected in the healthy father (Fig. 1c) and occurs with an allele frequency of 
0.00073% (allele count: 89/121922) within the Exome Aggregation Consortium (ExAC). Both G1522 and R1882 are 
completely conserved in all other 28 studied vertebrates (www.1000genomes.org). R1882G is not known to be present in 
unaffected individuals (www.1000genomes.org/, http://exac.broadinstitute.org/, http://www.ncbi.nlm.nih.gov/SNP/). 
DNA Sequencing of a cloned long range PCR fragment revealed that both variants are present on the identical allele in 
patient #2.  
Diagnostic gene panel sequencing was performed in patient #3 [16]. The same mutation (c.788C>T, p.Ala263Val) as 
previously described in patient #4 was detected in SCN2A [3]. Sequencing of both parents revealed that the mutation 
occurred de novo  
Functional studies. Electrophysiological analysis was first performed for the wild type (WT) channel in comparison 
with the de novo R1882G mutant, which was detected as the only SCN2A mutation in patient #1 (Fig 2). This analysis 
revealed a significant hyperpolarizing shift of the activation curve for mutant channels (Fig. 2d). We did not find 
significant differences for any other recorded gating parameter including current density (Fig. 2, Table 2, Online 
Resource 1 Fig. S1).  
Since patient #2 carries both the de novo R1882G mutation and the inherited variant G1522A on the same allele, we 
additionally analyzed mutant channels carrying (i) G1522A alone, and (ii) both G1522A and R1882G (Fig. 3). Mutant 
G1522A alone did not reveal any significant changes compared to WT channels. Interestingly, the double mutant 
channel did not show changes of the activation curve (Fig. 3e), as described above for R1882G alone. In contrast, the 
most prominent effect for the double mutation was a 1.7-fold increase in current density compared to the other three 
clones, i.e. WT, G1522A and R1882G alone (Fig. 3d, Table 2). In addition, we found a significant shift of the steady-
state fast inactivation curve towards more depolarized potentials only for channels carrying both variants (Fig. 3, Table 
2). Consistent with the increase in current density (as a measure for the number of functional channels in the membrane), 
Western blot analysis of transfected tsA201 cells -to study the amount of protein expression- revealed that the total 
NaV1.2 protein amount was significantly increased only in channels carrying both variants in comparison to the WT (Fig. 
4). 
We thus found differential gain-of-function effects for NaV1.2 channels carrying either the R1882G mutation alone or 
both variants, R1882G and G1522A. In both cases (R1882G alone or in combination with G1522A), the changes predict 
an increase of membrane excitability in neurons expressing mutant NaV1.2 channels.  
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Discussion 
We here describe patients carrying two different SCN2A mutations and comprising neonatal -onset seizures and 
childhood-onset episodic ataxia as the two main features. When we published the first case in 2010, it was not clear if the 
de novo A263V mutation in SCN2A was responsible alone for the main clinical symptoms, as migraine was a common 
feature in both branches of the family which could have influenced the phenotype of patient #4 [3]. Detection of a 
second patient (#3), with the same clinical key symptoms carrying the same mutation occurring independently de novo, 
now strongly suggests that this mutation is causative for both the seizures and episodic ataxia. Patients #1 and #2, 
carrying another de novo mutation in the same gene (in patient #2 occurring in combination with an inherited known rare 
polymorphism), corroborate these findings that the phenotype is caused by SCN2A gain-of-function mutations. This 
widens the spectrum of disorders combining epilepsy with other paroxysmal neurological symptoms such as dyskinesia 
or ataxia, which could be attributed to the expression of respective genes in different brain areas inducing an episodic 
dysfunction of neuronal networks [18-23].  
The clinical characteristics of these patients in comparison to other SCN2A-associated syndromes are that seizures 
recurred more frequently and persisted longer than in typical BFNIS and that those were more difficult to treat [24]. In 
contrast to more severe epileptic encephalopathies [9-15], the seizures still remitted after 5-13 months (except for few 
occasional later seizures in patient #4). Since drugs have been discontinued in patient #2, seizure freedom can be 
attributed to spontaneous remission, whereas this remains unclear in the other cases, as treatment has been continued 
(patients #1 and #3) or restarted after seizure relapse during a drug-free period (patient #4). Notably, seizures in patient 
#3 responded well to the Na+ channel blocker oxcarbazepine. Attacks of episodic ataxia with onset ranging 15 months to 
3.7 years of age were the most important symptom beside the seizures. Episodic headache was an additional feature 
occurring in all patients, although rare and uncertain in one, and could be accompanied by back pain, discomfort and 
vomiting. Treatment of episodic ataxia is more difficult. Patients #1 and #4 did not respond to acetazolamide. In 
addition, 4-aminopyridine, which works well in the clinically rather similar episodic ataxia type 2 [25,26], did not help 
patient #4. The effect of Na+ channel blockers, which work very well in the clinically distinct episodic ataxia type 1 with 
much shorter attacks triggered by sudden movements after rest [27-29], is not yet entirely clear in our patients. 
Theoretically, this group of antiepileptic drugs should counteract a gain-of-function of SCN2A mutations. There is 
increasing evidence that patients with severe early-onset epilepsies due to SCN2A mutations do respond to Na+ channel 
blockers [30]. However, network effects are difficult to predict and could influence the response to such drugs – also in a 
distinct way in different brain regions – as shown recently for the hippocampus [31]. 
Our previous and the here presented electrophysiological data clearly indicate that different gain-of-function effects of 
the detected mutations in SCN2A cause the clinical phenotype. Whereas the A263V mutation causes mainly an increased 
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persistent Na+ current [3], the de novo mutation R1882G found in patient #1 showed a hyperpolarizing shift of the 
activation curve. In contrast, the combination of both variants in the same channel subunit, as detected in patient #2, 
leads to a prominent increase in current density, confirmed by a larger amount of produced protein, and a depolarizing 
shift of the steady-state inactivation curve (but no shift of the activation curve). Until now, many BFNIS-associated 
SCN2A mutations – partly showing other gain-of-function mechanisms – rather exhibited a decrease in current density or 
cell surface expression, which however rarely reached statistical significance [3,7,17,32]. This confirms the peculiar 
importance of the increased current density of the combined variants found in patient #2. All observed effects predict an 
increased Na+ inflow and a neuronal hyperexcitability, which can explain the dysfunction of cortical or cerebellar 
networks causing the clinical symptoms of our patients. 
We have previously suggested that the age-dependent occurrence of seizures and remission in BFNIS could be due to the 
high NaV1.2 channel expression in axon initial segments of hippocampal and cortical pyramidal neurons early in 
development and their partial replacement by NaV1.6 channels with increasing maturation [7]. This mechanism could 
also contribute to seizure remission in the additional three cases. Although the episodic ataxia found in the studied 
patients might have many different causes, one hypothesis for later onset ataxia could be due to a delayed upregulation of 
NaV1.2 in cerebellar granule cells [7,33].  
Interestingly, different substitutions of the arginine at position 1882 (R1882Q and R1882L) have been identified in two 
de novo cases exhibiting epileptic encephalopathy [11] and intractable seizures, optic atrophy, severe intellectual 
disability, brain abnormalities and muscular hypotonia [13]. Furthermore, the A263V mutation has also been described 
as occurring de novo in monozygotic twins with Ohtahara syndrome and other unique neuropathologic abnormalities 
[34], and a A263T mutation has been identified in a patient with a different type of early-onset epileptic encephalopathy 
[12]. These observations indicate that not only the mutation determines the clinical phenotype, but that other factors such 
as the genetic background have to play a role in genotype-phenotype relationships. 
In summary, we here identified four patients with a common clinical phenotype (neonatal seizures and later onset ataxia) 
caused by SCN2A mutations, which enlarges the spectrum of neurological SCN2A-related phenotypes. 
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Tables 
Table 1 Main phenotypic characteristics of all four patients 
 Patient #1 (*2004) Patient #2 (*2006) Patient #3 (*2011) Patient #4 (*1999) 
Mutation c.5644C>G/p.R1882G c.4565G>C/p.G1522A 
c.5644C>G/p.R1882G 
c.788C>T/p.A263V c.788C>T/p.A263V 
Gender male female male male 
Exam at birth EEG at 42 con-
ceptional weeks 
slightly abnormal (see 
text) 
suspected amniotic 
infection syndrome 
muscular hypotonia 
and sleepiness 
hypomotor activity 
followed by TCS on 
alternating sides with 
contralateral ictal EEG 
discharges 
Age at seizure 
onset 
2 d 24 d 7 d 1 d 
Seizure type at 
onset 
bilateral TCS with 
reduced oxygen 
saturation and 
unresponsiveness 
multifocal CS and 
TCS lasting 10 s to  
2 min.  
bilateral TS TCS on alternating 
sides 
Other seizure 
types 
TCS, tendency to 
clustering 
GTCS during febrile 
infection 
TS evolving into 
secondary GTCS  
GTCS 
Treatment 
(duration) 
PB (7 mo); 
Acetazolamide  
(4 mo);  
VPA (10 y) 
PB (5 mo); CLZ+PHT 
(2 weeks);  
VPA (6 ½ y) 
Vit B6 (brief); PB 
(brief); TPM (brief); 
LEV (14 mo); OXC  
(3 y); LTG (5 mo);  
After Liao et al, 
2010[3]: 4-AP (12 d); 
Propranolol (7 mo); 
TPM (10 mo); 
LTG (7 mo) 
Seizure outcome 
(age) 
seizure-free  
(since age 5 mo) 
seizure-free  
(since age 5 mo) 
seizure-free  
(since age 7 mo) 
seizure-free (since age 
13 mo), isolated sei-
zures (3.5, 6.5, 14.5 y) 
Symptoms during 
childhood-onset 
episodic attacks 
paroxysmal dizziness 
and poor balance, 
slurred speech, ataxia, 
nausea, headache 
without vomiting 
slurred speech, 
impaired balance, 
ataxic gait, headache, 
rarely vomiting 
dizziness, unsteady 
gait, inability to walk, 
possibly rare painful 
episodes  
poor balance, ataxia, 
slurred speech, inter-
mittent myoclonic 
jerks, severe distress 
with headache, back 
pain, hypermotor acti-
vity, hyperventilation, 
retching or vomiting 
Age at onset, freq. 
and duration of 
episodes 
3.7 y ; 1–2/mo; a few 
min to several h 
20 mo; 1–10/w; 1-5 
min (rarely repeating 
over 2h) 
15 mo; 2-3/mo; 1 d 1.5 y; 1-3/mo;  
several h 
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*: year of birth; 4-AP: 4-aminopyridine; CLZ: clonazepam; d: day(s); CS: clonic seizure; GTCS: generalized tonic-
clonic seizure; h: hour(s); LTG: Lamotrigine; LEV: levetiracetam; min: minute(s); mo: month(s); OXC: oxcarbazepine; 
PB: phenobarbitone; PHT: Phenytoin; s: second(s); TS: tonic seizure; TCS: tonic clonic seizure; TPM: topiramate; VPA: 
valproate; w: week(s), y: year(s) 
 
Table 2 Current density and gating parameters for NaV1.2 WT and the mutations  
  Steady-state activation Steady-state inactivation Τrec [ms] 
 CD [pA/pF] V1/2 [mV] k V1/2 [mV] k N at -100 mV N 
SCN2A-WT -450.9±54.8 -28.2±1.0 -5.7±0.2 -69.4±0.7 5.2±0.1 16 5.2±0.4 10 
R1882G -356.7±57.2 -31.8±1.0$ -5.8±0.3 -67.8±0.8 5.7±0.3 12 5.8±0.6 12 
G1522A -448.0±78.1 -29.0±1.3 -5.3±0.3 -68.5±0.8 5.1±0.2 12 5.0±0.5 12 
G1522A/ 
R1882G 
-757.4±136.3# -28.8±1.2 -4.8±0.3* -64.3±0.9& 5.2±0.1 11 4.0±0.4 11 
Data are presented as means ± s.e.m. k: slope factor.  
$the R1882G mutant is significantly different from the WT (p<0.05, t-test). 
#the G1522A/R1882G double mutant is significantly different from the three other clones (p<0.05, one way ANOVA 
with Bonferroni posthoc test).  
*the G1522A/R1882G double mutant is significantly different from the R1882G mutant (p<0.05, one way ANOVA with 
Bonferroni posthoc test).  
&the G1522A/R1882G double mutant is significantly different from WT (p<0.001), from G1522A (p<0.01) and R1882G 
(p<0.05, one way ANOVA with Bonferroni posthoc test) 
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Figure legends 
Fig.1 Pedigrees and SCN2A mutations in three additional cases with neonatal epilepsy and late-onset episodic ataxia. (a-
c) Pedigrees of patients #1 (a), #2 (b) and #3 (c). The index patients are indicated by arrows. “+” denotes a wild type 
allele. A grandmother with reported Menière’s disease (a) and an aunt with reported neonatal-onset seizures (c) are 
marked in gray. Patients #1 and #3 carry one de novo SCN2A mutation each (a, c), whereas patient #2 carries both an 
inherited variant and a de novo SCN2A mutation on the same allele (b). (d) Sequence chromatograms of patient #2 and 
the unaffected parents showing a previously described, heterozygous c.4565G>C variant in the father and the patient, 
and an additional c.5644C>G mutation only in the patient. (e) Structure of the human NaV1.2 Na+ channel α subunit 
showing the locations of all three mutations (A263V: orange circle, G1552A: green circle, R1882G: blue circle). (f) 
A263V, G1522 and R1882 (red boxed) and the surrounding amino acids show high evolutionary conservation 
 
Fig.2 Functional studies reveal a gain-of-function for the R1882G mutation. (a-b) Families of whole-cell Na+ currents 
recorded from tsA-201 cells transfected with either SCN2A-WT (a) or R1882G (b) mutant channels. Sodium currents 
were elicited by 24 ms long step depolarizations ranging from -105 to + 97.5 mV from a holding potential of -140 mV. 
(c) The current density revealed no significant change in mean whole-cell peak current for R1882G mutant channels. (d) 
Voltage-dependence of steady-state Na+ channel activation and inactivation revealing a significant hyperpolarizing shift 
in the activation curve for R1882G mutant channels compared with the WT (*p<0.05, t-test). Lines represent fits of 
Boltzman functions. (e) The time course of recovery from fast inactivation determined at -100 mV showed no significant 
changes between WT and mutant channels. Lines represent fits of exponential functions yielding the time constant Τ rec. 
All values of electrophysiological results, numbers and p-values are listed in Table 2 and are shown as mean ± SEM 
 
Fig.3 Functional studies reveal a different gain-of-function mechanism when both mutations G1522A/R1882G are 
combined. (a-c) Families of whole-cell Na+ currents recorded from tsA-201 cells transfected with either SCN2A-WT (a), 
G1522A mutant channels (b) or G1522A/R1882G mutant channels (c). Sodium currents were elicited as in Fig. 2. (d) 
The current density was significantly (1.7-fold) increased for G1522A/R1882G mutant channels (*p<0.05, one way 
ANOVA with Bonferroni posthoc test, Table 2). (e) Voltage-dependence of steady-state Na+ channel activation and 
inactivation revealing a significant depolarizing shift of the inactivation curve for G1522A/R1882G mutant channels 
(from WT ***p<0.001, from G1522A **p<0.01, one way ANOVA with Bonferroni posthoc test, Table 2). Lines 
represent fits of Boltzman functions. (f) Time course of recovery from fast inactivation at -100 mV, as described in Fig. 
2, did not reveal significant changes between WT and mutant channels. All values of electrophysiological results, 
numbers and p-values are listed in Table 2 and are shown as mean ± SEM 
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Fig.4 Western Blot Analysis shows a significant increase in expression level only for the G1522A/R1882G mutation. (a) 
Representative experiment illustrating total NaV1.2 protein expression of tsA201 cells transfected with: only transfection 
reagent as Mock control, WT-NaV1.2, only G1522A, only R1882G or both G1522A/R1882G and detected with anti- pan 
sodium channel antibody. The immunoreactive bands of Mock-control, NaV1.2-WT or mutant proteins were normalized 
to the amount of the endogenous membrane-cytoskeletal protein Vinculin. (b) Quantification of six independent 
experiments by normalizing the signals of NaV1.2 protein bands to the corresponding Vinculin signals in total lysates 
demonstrated that each mutation exposed a higher level of Na+ channel expression, but only G1522A/R1882G presented 
a significant increase of the expression level compared to the WT (**p<0.01; N=6, one way ANOVA with Bonferroni 
posthoc test). All values are shown as mean ± SEM 
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